Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,101–13,200 of 15,747
SARS-CoV-2 infection in children and the Turkish Archives of Pediatrics
Kasapçopur, Ö. (2020) · Turkish Archives of Pediatrics · doi:10.5152/turkarchpediatr.2020.231220 · Cited by 1
Jin, J., & Li, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14828 · Cited by 1
Vaccine Development and Immune Responses in COVID-19: Lessons from the Past
Fatemi, F., Nejad, Z. H., & Siadat, S. E. R. (2021) · Springer eBooks · doi:10.1007/978-981-16-3108-5_5 · Cited by 1
Tani, N., Ikematsu, H., Goto, T., Kondo, S., Gondo, K., Fujiyoshi, N., Minami, J., Harada, Y., Nagano, S., Horiuchi, T., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.051 · Cited by 1
Bian, Z.-Z., Wu, Z., Liu, N., et al. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00756-w · Cited by 1
“2021) and BNT162b2 (Polack et al. 2020) are partially due to the difference in APOBEC activity and the extent of C-to-U RNA editing.”
BackgroundCellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2
Tovar, V., Sánchez, I. P., Rugeles, M. T., Taborda, N. A., & Hernández, J. C. P. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70375 · Cited by 1
“With an efficacy of 95% in preventing COVID‐19 disease, including severe cases in individuals without prior infection, their impact has been significant [101, 102].”
Surgery during the COVID-19 pandemic: Don't wait to vaccinate
Cochrun, S. L., & Marrazzo, J. M. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.05.022 · Cited by 1
“In randomized clinical trials, both vaccines significantly reduced rates of severe infection, including hospitalization, and mortality, and extent of community uptake has been directly associated with lower community burden of severe disease.(2,3) The primary series of both of these vaccines is administered as two dos…”
Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses
Zhang, B., Liu, Y., Chen, T., Lai, J., Liu, S., Liu, X., Zhu, Y., Rao, H., Peng, H., & Ma, X. (2025) · Vaccines · doi:10.3390/vaccines13111168 · Cited by 3
“By December 2020, two mRNA vaccines, named BNT162b2 and mRNA-1273, which were developed by Pfizer-BioNTech and Mod-erna, respectively, had received EUA in the United States [204,205].”
Schmidt, K. G., Harrer, E. G., Schönau, V., Simón, D., Kleyer, A., Steininger, P. A., Korn, K., Schett, G. A., Knobloch, C. S., Nganou‐Makamdop, K., et al. (2023) · Infection · doi:10.1007/s15010-023-02035-6 · Cited by 1
Optimization Algorithm Based on Novelty Search Applied to the Treatment of Uncertainty in Models
Martínez‐Rodríguez, D. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/178994 · Cited by 1
Hirano, H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.688 · Cited by 1
Delayed Recurrent Erythema Nodosum Following COVID-19 Vaccine: A Case Report
Alghamdi, N., Alamrie, R. M., Alshafie, A. Y., et al. (2023) · Cureus · doi:10.7759/cureus.42776 · Cited by 1
“The efficacy of the Pfizer vaccine/BNT162b2 against COVID19 infection is 95% and was found to show some common local reactions such as redness, pain, and swelling [7].”
BackgroundVila‐Candel, R., Martín-Arribas, A., Castro‐Sánchez, E., Escuriet, R., & Martin-Moreno, J. M. (2023) · Healthcare · doi:10.3390/healthcare11212833 · Cited by 3
Logrieco, M. G., Logrieco, G., Nicolì, I., Pignatelli, F., Lionetti, F., Traglia, F., Spinelli, M., Domenico, A. D., & Fasolo, M. (2022) · Vaccines · doi:10.3390/vaccines10060854 · Cited by 1
“This is even more important because most vaccine platforms use a two-dose prime boost approach to generate an immune response [81].”
BackgroundVaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan
Hiroi, S., Morikawa, S., Motomura, K., & Mori, H. (2023) · Access Microbiology · doi:10.1099/acmi.0.000465.v3
Wu, W., & Wang, Z. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2517363 · Cited by 3
“This route expands the utility of mRNA therapeutics beyond prophylactic vaccines and toward treatments for genetic disorders, cancers, and chronic diseases [6–8].”
Lipid Nanoparticles for Drug Delivery
Zhou, Y., Jiang, R., & Chen, W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34203-5.00003-6 · Cited by 1
Chen, Y., Li, J., Duangdany, D., Phamisith, C., Yu, B., Lan, S., Jin, L., Lv, D., Li, Y., Luo, B., et al. (2023) · medRxiv · doi:10.1101/2023.09.11.23295344 · Cited by 2
The Impact of Vaccination on COVID-19 Outcomes in Vietnam
Nguyen, N.-L. T., Nguyen, H. T. T., Le, V. Q., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14242850 · Cited by 1
“Despite multiple randomized clinical trials validating vaccine efficacy, there remained a need for a greater understanding of the effectiveness of booster shots and mix-and-match vaccines (a combination of different types of COVID-19 vaccines) [8,15,16].”
Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine AdministrationPreprint
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · doi:10.36227/techrxiv.16794724.v1
Mattar, C. N. Z., Koh, W. L. C., Seow, Y., Hoon, S. S., Venkatesh, A., Dashraath, P., Lim, L. M., Ong, J., Lee, R. J. Y., Johana, N. B., et al. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021447 · Cited by 1
Salvadori, M. (2022) · Transplantology · doi:10.3390/transplantology3040030
Mavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.4
Risk Assessment of COVID-19 Vaccination Among Childbearing Women.
Tsiorou, K., & Sarantaki, A. (2022) · PubMed Central · doi:10.26574/maedica.2022.17.2.449 · Cited by 1
COVID-19 Epidemic Forecasting and Cost-Effectiveness Analysis: A Case Study of Hong Kong
Tao, W., Guo, H., Xu, Q., & Yu, D. (2021) · Lecture notes in operations research · doi:10.1007/978-3-030-90275-9_28 · Cited by 2
García, S. L. B. (2022) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001599 · Cited by 1
Ndishimye, P., Martinez, G. S., Hewins, B., Ostadgavahi, A. T., Kumar, A., Sharma, M., Karuhije, J., Nkeshimana, M., Nsanzimana, S., & Kelvin, D. J. (2023) · medRxiv · doi:10.1101/2023.03.05.23286509 · Cited by 1
“Early results of mRNA vaccine trials suggested they would be effective at preventing, or slowing the pandemic (CDC, 2021; Polack et al., 2020).”
BackgroundQuinn, M. A., Parra-Rodriguez, L., Alsoussi, W. B., Ayres, C., Klebert, M. K., Liu, C., Suessen, T., Scheaffer, S. M., Middleton, W. D., Teefey, S. A., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200920 · Cited by 1
Sgherza, N., Zucano, S., Vitucci, A., et al. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.056 · Cited by 1
Sugiura, T., Sugiura, H., Kato, H., Nariai, Y., Mizumoto, Y., Hanada, K., Takahashi, R., Hinotubo, Y., Tanaka, N., Sasaki, M., et al. (2022) · Infectious Disease Reports · doi:10.3390/idr15010003 · Cited by 1
“A two-dose regimen of the BNT162b2 vaccine by Pfizer-BioNTech confers 95% protection against COVID-19 [1].”
BackgroundLupu, C. D., Cotuţiu, V.-D., & Bîrluțiu, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083030 · Cited by 1
“Mass vaccination, from late 2020, reduced hospitalizations despite uneven uptake [7,8].”
Volkman, H. R., Nguyen, J. L., Mustapha, M. M., et al. (2024) · Vaccines · doi:10.3390/vaccines12101174 · Cited by 1
“%] versus 94.1% [89.3 to 96.8%], respectively) [2,3].”
InfluentialEvaluation of compressed sodium chloride on the inactivation of SARS-CoV-2 and surrogates
Bhavanam, S., Lee, B. E., Qiu, Y., Zelyas, N. J., & Pang, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277881 · Cited by 1
“Although vaccines are now available [6,7], there are still significant challenges to achieving global population-wide immunization within a short period of time.”
BackgroundRisk of SARS-CoV-2 infection following initial COVID-19 vaccination: Population-based cohort study
Tadrous, M., Chung, H., Men, S., Chu, C., Campbell, T. J., Juurlink, D. N., Kwong, J. C., Paterson, J. M., & Gomes, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273903 · Cited by 1
Lidström, A.-K., Albinsson, B., Sund, F., Lindbäck, J., van Hunsel, F. P. A. M., Fall, T., & Westman, G. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127553 · Cited by 1
The Impact of SARS-CoV-2 on Work Absence
Etli, D., Wiewior, A., Malone, A., Locke, K., Bullock, N., & Howard, R. (2024) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000003289
“11 Thompson et al 12 specifically examined the effectiveness of the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines among health care personnel, first responders, and other frontline workers.”
Shqara, R. A., Wolf, M. F., Mustafa, S. M., et al. (2023) · American Journal of Perinatology · doi:10.1055/a-2090-5402 · Cited by 1
Crown, W. H., Britton, E., Razavi, M., Luan, Y., Veerunaidu, S., Kates, J., Gaumer, G. L., Jordan, M., Hurley, C. L., & Nandakumar, A. K. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251367510 · Cited by 1
“9 However, the widespread use of school closures and online instruction has had long-term effects on the learning of children.”
Sakr, S., Khatib, A. A., BouRaad, R., Karaki, N., Said, H. E., Sheet, I., & Hamam, B. (2022) · The Open Public Health Journal · doi:10.2174/18749445-v15-e221213-2022-67 · Cited by 2
Kisakova, L. A., Ilyicheva, S. A., & Рудометов, А. П. (2026) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-026-06645-6 · Cited by 1
“The mRNA-based COVID-19 vaccines developed by Moderna and Pfizer/BioNTech, which utilize lipid nanoparticle (LNP) encapsulation, have demonstrated high efficacy and acceptable safety profiles [2].”
Need For Focused Pharmacovigilance in the Face of Rapid COVID-19 Vaccine Development
Kaur, U., & Chakrabarti, S. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220928151519 · Cited by 1
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination
Braverman, G., Barbhaiya, M., Nong, M., et al. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.08.005 · Cited by 1
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV
Lucey, M., Burns, F. M., Bhagani, S. R., et al. (2025) · AIDS · doi:10.1097/qad.0000000000004180 · Cited by 1
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccinePreprint
Yechezkel, M., Mofaz, M., Patalon, T., et al. (2022) · medRxiv · doi:10.1101/2022.06.07.22276117 · Cited by 1
Sun, J., Yang, M., Su, G., Wang, L., Hu, X., Zhou, Y., Cui, G., Qian, G., Yuan, Y., Hu, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202405679 · Cited by 1
Babayemi, O. H., Fotso, C. M., Chaudhuri, S., Sablatura, L. K., Baker, C., Velasquez, F. C., Morton, J., Sevick-Muraca, E. M., & Sirianni, R. W. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102877 · Cited by 6
La lutte contre la fraude scientifique : une tâche ingrate mais nécessaire
Barrière, J., Frank, F., Besançon, L., Samuel, A., Saada, V., Billy, E., Seitz‐Polski, B., & Robert, J. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.06.013 · Cited by 1
Öztürk, B., Öztürk, S., Çağlar, A., Kaçer, İ., Hacımustafaoğlu, M., & Öztürk, K. (2021) · Journal of Emergency Nursing · doi:10.1016/j.jen.2021.03.013 · Cited by 1
Kornek, B., Leutmezer, F., Rommer, P. S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924204 · Cited by 1
Bayesian Analysis of NPI and Vaccination Effects on SARS-CoV-2 Transmission in South Korea 2020–2022
Yang, C., & Jeong, Y. S. (2026) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2026.56.1.058 · Cited by 1
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
Gaur, A., & Chirmule, N. B. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_62 · Cited by 1
COVID-19 Vaccinated Individuals Can Be a Source of SARS-CoV-2 Transmission—A Systematic Review
Kampf, G. (2021) · Hygiene · doi:10.3390/hygiene1010001 · Cited by 1
“8 ◦C, cough, shortness of breath, anosmia or ageusia [7]; at least two of the following symptoms: fever (temperature ≥ 38 ◦C), chills, myalgia, headache, sore throat, or new olfactory or taste disorder, or as occurring in those who had at least one respiratory sign or symptom (including cough, shortness of breath, or…”
BackgroundKhan, S., Hosseinian, S., de Assis, R., Khalil, G., Luu, M. K., Jain, A., Horvath, P., Nakajima, R., Palma, A. M., Hoang, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2180753/v1 · Cited by 1
Recommendations and effect of COVID-19 vaccines
Hamed, R. A. E., Aziz, A. A., & Ali, M. R. K. (2022) · Sohag Medical Journal · doi:10.21608/smj.2022.118976.1302 · Cited by 1
For “U” the bell tolls: Pseudouridine evades TLR detection
Young, A. P., & Kanneganti, T. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.08.008 · Cited by 1
Time-ordered-expression mRNA (TOE mRNA) for melanoma RNA vaccines
Zhang, X., Teng, X., Dai, Y., Gong, N., Zhang, Q., Hu, D., Wu, Y., Hou, H., & Li, J. (2026) · Chemical Science · doi:10.1039/d5sc07482g · Cited by 2
Naka, T., Funato, M., Yasuda, K., Nakayama, T., & Kuru, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479321 · Cited by 1
Intarapanya, T., Suratanee, A., Pattaradilokrat, S., & Plaimas, K. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8030175 · Cited by 1
“The third type is an mRNA vaccine obtained by synthesizing the genetic code mRNA that encodes the viral spike protein, such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 vaccine (Moderna) [12].”
BackgroundMei, A., Senthinathan, A., Hussain, S., Tadrous, M., Noonan, V. K., Jaglal, S. B., Moineddin, R., Craven, B. C., McKay, S. M., Cadel, L., et al. (2024) · Healthcare · doi:10.3390/healthcare12171799 · Cited by 1
Takagi, A., & Matsui, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.21.461322 · Cited by 1
Hederman, A. P., Brookes, H. M., Natarajan, H., Heyndríckx, L., Ariën, K. K., Weiner, J. A., Rottenstreich, A., Zarbiv, G., Wolf, D. G., Goetghebuer, T., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013408 · Cited by 2
Individual well-being and national determinants of screening mammography among women over fifty
Hovav, B., & Brammli‐Greenberg, S. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02389-3 · Cited by 1
Eficacia y Eventos Adversos de Vacunas contra el SARS CoV-2, autorizadas en los años 2020 y 2021
Olaya, P. (2023) · ACC CIETNA Revista de la Escuela de Enfermería · doi:10.35383/cietna.v10i1.893 · Cited by 1
“En esta revisión se incluyó a la población mayor de 16 años de ambos sexos y todos los estudios analizados (15) fueron con enfoque cuantitativo, los cuales determinan si son eficaces”
BackgroundDevelopment and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint
Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · Authorea · doi:10.22541/au.162615692.26217047/v2 · Cited by 1
Rahimnahal, S., Yousefizadeh, S., & Mohammadi, Y. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0334662 · Cited by 1
“Several SARS-CoV-2 vaccines have been developed and reported to date [33,82–85].”
Waning and boosting of functional humoral immunity to SARS-CoV-2Preprint
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Lévican, J., Poblete, E., Salina, E., Muñoz, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.22.501163 · Cited by 1
“Previous work has shown that nearly all clinically approved COVID-19 vaccines elicit Spike-specific antibodies and can confer protection against wildtype virus induced disease (30, 39-42).”
BackgroundArashiro, T., Berba, R. P., Calayo, J. P., Kris, M., Garcia, R. M., Suzuki, S., Dungog, C. C., Rivera, J., Malijan, G. M., Agrupis, K. A., et al. (2025) · Western Pacific surveillance response journal · doi:10.5365/wpsar.2025.16.1.1131 · Cited by 1
COVID-19 Tanı Testleri, Tedavisindeki Aşılar ve İlaçlar; Güncel Durum
Salmanoglu, D. S., Çalışkan, E. E., Meliz, S. O. F. U., Uyanıkgil, Y., & Çetin, E. Ö. (2021) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.957260 · Cited by 6
Progress in Pharmaceutical Sciences and Future Challenges
Cacabelos, R. (2024) · Life · doi:10.3390/life14121636 · Cited by 1
Wang, X., Mahmood, S. F., Jin, F., Cheah, W. K., Ahmad, M., Sohail, M. A., Ahmad, W., Suppan, V. K. L., Sayeed, M. A., Luxmi, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4066508 · Cited by 1
Fantin, R. F., Clark, J. J., Cohn, H., Jaiswal, D., Bozarth, B., Civljak, A., Rao, V., Lobo, I., Nardulli, J., Srivastava, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.15.602781 · Cited by 1
Chen, C., Lovendahl, K. N., Overbaugh, J. M., & Lee, K. K. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013143 · Cited by 1
Smyth, C. H., Mollé, L. M., McLeod, V. M., Chen, M. Z., & Johnston, A. P. R. (2026) · Small Science · doi:10.1002/smsc.70313 · Cited by 2
Pawlowski, C., Rincón-Hekking, J., Awasthi, S., et al. (2021) · doi:10.31219/osf.io/czn7j · Cited by 1
A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in ChinaPreprint
Yao, Y., Yang, Y., Wu, Q., et al. (2023) · medRxiv · doi:10.1101/2023.02.28.23286535 · Cited by 1
Model analysis of vaccination effectiveness by state in the United StatesPreprint
Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3987537 · Cited by 1
Wang, Y., Hu, Y., Ma, Y., Li, P., Zhou, S., Xu, M., He, B., Liu, S., Lv, K., Liu, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.11.037 · Cited by 1
Self-citationAraújo, O., Gómez-Cerquera, J. M., & Espinosa, G. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.09.011 · Cited by 1
“Of the four COVID19 vaccines authorized by European regulatory agencies so far (Pfizer, Moderna, Astra-Zeneca and Janssen), only the clinical trials of the first included patients with rheumatological diseases [2].”
Symptomatic Acute Myopericarditis after Pfizer Vaccine against COVID-19
Giublin, I. T., Hartmann, C., Mangili, O. C., Shiozaki, A. A., & Moura, L. Z. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220023 · Cited by 1
The Vaccines Induced Autoimmunity
Giri, P. S., Shoenfeld, Y., & Dwivedi, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-4800-8_2 · Cited by 2
Development and Evaluation about “2nd-wave” COVID-19 Vaccines
Araki, Y. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00234-3 · Cited by 1
POx-Lipids as an Alternative to PEG-Lipids? Multimethod Assessment of Chemistry and Structure
Tsarenko, E., Anufriev, I. E., Holick, C. T., Klein, T. R., Schubert, S., Fritz, N., Hoeppener, S., Schubert, U. S., & Nischang, I. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07351 · Cited by 3
Andanigoudar, K. B., Bant, D., Shalini, H., et al. (2022) · National Journal of Community Medicine · doi:10.5455/njcm.20211216122011 · Cited by 1
COVID-19 vaccine: Potential candidates, achievements, and challenges
Shoaib, M., Waheed, A., Wajid, M., Urwa, H., Khan, T. S., Khan, M. S., Aslam, M. W., Ahmad, S., Jafar, K., Akmal, H., et al. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.15.3.0145 · Cited by 1
“Another RNA-based vaccine, BNT162b2 was developed by Pfizer and BioNtech [19].”
BackgroundQuantifying the real-life impacts of vaccination on critical COVID-19Preprint
Sofonea, M. T., Boennec, C., Fontalirant, A., Regnat, M., Lefrant, J., Alizon, S., & Fischer, M.-O. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/6ebxu · Cited by 3
Aging and the Ethics of Longevity Science
Farrelly, C. (2026) · doi:10.1093/9780197830062.001.0001 · Cited by 2
Real-time evaluation and adaptation to facilitate rapid recruitment in a large cohortPreprint
Honushefsky, A. M., Wagner, E. S., Sheridan, K. M., et al. (2023) · medRxiv · doi:10.1101/2023.01.30.23285102 · Cited by 1
“For example, SARS-CoV-2 vaccine trials demonstrated the potential for rapid public health impact when trials reach enrollment goals quickly and effectively.(1-2) Rapid enrollment of large cohorts is also important in studies with regulatory implications that are not as imminent as a vaccine for a global pandemic but r…”
BackgroundSonoda, J., Mizoguchi, I., Yamaguchi, N., Horio, E., Miyakawa, S., Xu, M., Yoneto, T., Katahira, Y., Hasegawa, H., Hasegawa, T., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094442 · Cited by 3
“Messenger RNA vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which are currently being used successfully around the world [1,2], have shown strong prophylactic efficacy and safety when injected intramuscularly with a needle syringe [3].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.